000280424 001__ 280424
000280424 005__ 20250907001849.0
000280424 0247_ $$2doi$$a10.1162/IMAG.a.33
000280424 0247_ $$2pmid$$apmid:40800757
000280424 0247_ $$2pmc$$apmc:PMC12319754
000280424 0247_ $$2altmetric$$aaltmetric:178083245
000280424 037__ $$aDZNE-2025-00951
000280424 041__ $$aEnglish
000280424 082__ $$a610
000280424 1001_ $$aHaudry, Sacha$$b0
000280424 245__ $$aEffects of an 18-month meditation training on dynamic functional connectivity states in older adults: Secondary analyses from the Age-Well randomized controlled trial.
000280424 260__ $$aCambridge, MA$$bMIT Press$$c2025
000280424 3367_ $$2DRIVER$$aarticle
000280424 3367_ $$2DataCite$$aOutput Types/Journal article
000280424 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1755501447_27484
000280424 3367_ $$2BibTeX$$aARTICLE
000280424 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000280424 3367_ $$00$$2EndNote$$aJournal Article
000280424 520__ $$aMeditation training in older adults has been proposed as a non-pharmacological intervention to promote healthy aging and lower the risks of developing Alzheimer's disease (AD). Resting-state dynamic functional network connectivity (dFNC) highlighted two brain states, the 'strongly connected' and 'default mode network (DMN)-negatively connected' states, associated with protective factors for dementia including AD, and two states, the 'weakly connected' and 'salience-negatively connected' states, associated with risk factors for dementia. In this study, we aimed at assessing the impact of an 18-month meditation training on dFNC states in older adults. One hundred and thirty-five healthy older adults were randomized (1:1:1) to 18-month meditation training, 18-month non-native language training, or no intervention. dFNC of the DMN, salience, and executive control networks was assessed in 124 individuals using a sliding window framework, and states were obtained by k-means clustering. Linear mixed models evaluated the change in time spent in different connectivity 'states' and the number of transitions between states for each group and between groups. Only participants in the meditation group transitioned significantly more between states (p = 0.008, d = 0.52), with a significant between-group difference with the non-native language training group (p = 0.001). Moreover, only the meditation group showed a change in time spent in specific states, spending less time in the 'weakly connected' state (p = 0.009, d = -0.44) and more time in the 'strongly connected' state (p = 0.03, d = 0.46), but there was no difference between groups. Brain states at rest were significantly impacted by an 18-month meditation intervention, with increased number of transitions between states, an increased time spent in the 'strongly connected' state, and decreased time spent in the 'weakly connected' state. While only the first change differed significantly between groups, these results suggest a beneficial effect of meditation through a reduction in dFNC metrics associated with AD risk factors and an increase in dFNC metrics associated with protective factors. However, the absence of a significant group-by-time interaction for time spent in states, the small effect sizes, and the fact that the sample size was not powered for this outcome limit the interpretation of the findings. Additionally, unmeasured factors such as genetic predisposition and lifestyle could have influenced the results. Future studies should identify the specific active mechanisms of meditation underlying these effects to optimize interventions. Trial Registration: The Age-Well randomized controlled trial (RCT) was approved by the local ethics committee (CPP Nord-Ouest III, Caen; trial registration number: EudraCT: 2016-002441-36; IDRCB: 2016-A01767-44; ClinicalTrials.gov Identifier: NCT02977819; registration date: 2016-11-25).
000280424 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000280424 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000280424 650_7 $$2Other$$aAD protective factors
000280424 650_7 $$2Other$$aAD risk factors
000280424 650_7 $$2Other$$adynamic functional connectivity
000280424 650_7 $$2Other$$ameditation
000280424 650_7 $$2Other$$aneuroimaging
000280424 650_7 $$2Other$$anon-pharmacological intervention
000280424 7001_ $$aDautricourt, Sophie$$b1
000280424 7001_ $$aGonneaud, Julie$$b2
000280424 7001_ $$aLandeau, Brigitte$$b3
000280424 7001_ $$aCalhoun, Vince Daniel$$b4
000280424 7001_ $$ade Flores, Robin$$b5
000280424 7001_ $$aPoisnel, Geraldine$$b6
000280424 7001_ $$aBougacha, Salma$$b7
000280424 7001_ $$0P:(DE-2719)9002169$$aKuhn, Elizabeth$$b8$$udzne
000280424 7001_ $$aTouron, Edelweiss$$b9
000280424 7001_ $$aChauveau, Léa$$b10
000280424 7001_ $$aFelisatti, Francesca$$b11
000280424 7001_ $$aPalix, Cassandre$$b12
000280424 7001_ $$aVivien, Denis$$b13
000280424 7001_ $$ade la Sayette, Vincent$$b14
000280424 7001_ $$aLutz, Antoine$$b15
000280424 7001_ $$00000-0002-4889-7932$$aChételat, Gaël$$b16
000280424 773__ $$0PERI:(DE-600)3167925-0$$a10.1162/IMAG.a.33$$gVol. 3, p. IMAG.a.33$$pIMAG.a.33$$tImaging neuroscience$$v3$$x2837-6056$$y2025
000280424 8564_ $$uhttps://pub.dzne.de/record/280424/files/DZNE-2025-00951.pdf$$yOpenAccess
000280424 8564_ $$uhttps://pub.dzne.de/record/280424/files/DZNE-2025-00951%20SUP.pdf
000280424 8564_ $$uhttps://pub.dzne.de/record/280424/files/DZNE-2025-00951%20SUP.pdf?subformat=pdfa$$xpdfa
000280424 8564_ $$uhttps://pub.dzne.de/record/280424/files/DZNE-2025-00951.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000280424 909CO $$ooai:pub.dzne.de:280424$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000280424 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002169$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000280424 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000280424 9141_ $$y2025
000280424 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000280424 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-09-26T09:40:26Z
000280424 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-09-26T09:40:26Z
000280424 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000280424 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-09-26T09:40:26Z
000280424 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2025-01-02
000280424 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-02
000280424 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2025-01-02
000280424 9201_ $$0I:(DE-2719)1011201$$kAG Wagner$$lNeuropsychology$$x0
000280424 980__ $$ajournal
000280424 980__ $$aVDB
000280424 980__ $$aUNRESTRICTED
000280424 980__ $$aI:(DE-2719)1011201
000280424 9801_ $$aFullTexts